CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

SYNDEO Medical, a Belgium-based leader in diagnostic and interventional procedural solutions, announces that its two flagship product brands, SYNDEOPack Interventional Procedure Packs™ and Xssential ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups look to build on former ...

Integra Lifesciences appointed former 3M executive Mojdeh Poul as CEO. Poul will take over from Jan De Witte in January, ...

Roots Community Health has sued 12 other firms, including GE Healthcare, CVS and Walgreens, and called for manufacturers and ...

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.